Table 1.
Baseline Characteristics of Mothers in Cohort
| Perinatally Acquired HIV (n=14) | Behaviorally Acquired HIV (n=60) | P-value | |
|---|---|---|---|
| Age of Mother, years (Median) (IQR) | 20 (19-23) | 30 (23-37) | < 0.001 |
| Race, No. (%) | 0.8 | ||
| White | 0 (0) | 1 (2) | |
| African American | 10 (71) | 38 (59) | |
| Hispanic | 4 (29) | 25 (39) | |
| Asian | 0 (0) | 1 (2) | |
| Marital Status, No. (%) | 0.3 | ||
| Single | 13 (93) | 47 (79) | |
| Married | 0 (0) | 11 (18) | |
| Living with partner | 1 (7) | 2 (3) | |
| Substance Abuse, No. (%) | 0.6 | ||
| Prior to pregnancy | 6 (43) | 31 (52) | |
| During pregnancy | 1 (7) | 10 (17) | |
| Maternal Height, cm (Median) (IQR) | 155 (154-159) | 162 (155-168)‡ | 0.71 |
| History of Opportunistic Infections, No. (%) | 6 (43) | 6 (10) | 0.008 |
| Nadir CD4+ cells/mm3 during pregnancy (Median, IQR) | 271 (38-374) | 391 (283-544) | |
| Nadir CD4+ cells ≤200 cells/mm3 during pregnancy | 9 (64) | 5 (36) | 0.01 |
| HIV RNA level <400 copies/mL at delivery | 10 (71) | 52 (87) | 0.2 |
| Combination ART (cART), No. (%) | |||
| Second-line cART * | 6 (43) | 0 (0) | <0.001 |
P-values from Wilcoxon test for continuous variables and Chi-square or Fisher's exact for categorical variables.
‡
n=53 women with BAH
*
Second-line cART includes: Enfuvirtide, Etravirine, Darunavir, and Raltegravir